Canadians who choose this route accept risks including uncertain purity and potency, lack of medical supervision, no recourse if products are substandard, and potential legal complications
In the previous KFF poll, about half of all adults who took a GLP-1 drug said it was hard for them to afford it
And since retatrutide is not legally on the market, its risky to seek it out, since you cant be sure its legitimate
This outcome positions retatrutide as a highly effective candidate, potentially more so than current treatments like semaglutide (Wegovy) and tirzepatide (Zepbound)
In his recent article, Dr
Glucagon-driven lipolysis may confer an advantage specifically in metabolic-associated steatotic liver disease (MASLD), and phase 3 MASLD sub-studies for retatrutide are ongoing